Yu Dechao

Dr. Yu Dechao (“Dr. Yu”), the founder, executive director, chairman of the board of directors and chief executive officer of the company, is mainly responsible for the overall strategic planning, business direction control and management of the Group. Dr. Yu is a Ph.D. in genetics from the Chinese Academy of Sciences and a postdoctoral fellow at the University of California, San Francisco. It is his ideal to develop high-quality biological medicines that ordinary people can afford.

Dr. Yu has been engaged in biopharmaceutical innovation research for more than 20 years. He is a scientist who invented three "National Class 1 New Drugs" and promoted the development and marketing of new drugs. Dr. Yu invented the world's first marketed oncolytic immunotherapy anti-tumor drug "Ankerui®" (recombinant human adenovirus type 5 injection), pioneering the use of viruses to treat tumors; he co-invented and He led the development of China's first new monoclonal antibody drug "Langmu®" (Conbercept Ophthalmic Injection) with global intellectual property rights, which changed the history of China's blind patients with fundus diseases who had no domestic drugs to treat them; he jointly Invented and led the development of "Tavyt®" (sintilimab injection), which was approved for marketing on December 24, 2018, for the treatment of relapsed or refractory classical Hodgkin's lymphoma (r/r cHL ), is currently the PD-1 inhibitor with the most clinical evidence of first-line treatment in the world.

Dr. Yu has successively served as the vice president of new drug research and development of Calydon Biopharmaceutical Company in the United States, the chief scientist of Cell Genesys Pharmaceutical Company in the United States (later listed on NASDAQ, stock code: CEGE), and the chief scientist of Applied Genetic Technology Corporation in the United States (later listed on NASDAQ). , stock code: AGTC) vice president of research and development, director, president and CEO of Chengdu Kanghong Biotechnology Co., Ltd., director and vice president of Chengdu Kanghong Pharmaceutical Group.

Dr. Yu is currently a professor and doctoral supervisor at Sichuan University, a part-time researcher at Shanghai Institute of Materia Medica, Chinese Academy of Sciences, a visiting professor at Zhejiang University, an industry professor at Soochow University, chairman of the board of directors of the Chinese Antibody Association, deputy director of the Drug Research and Development Committee of China Pharmaceutical Innovation Promotion Association, and China Immunology Deputy Director of the Society of Tumor Immunology and Tumor Biotherapy Professional Committee, Standing Director of China Medical Biotechnology Association, Member of Tumor Biotherapy Professional Committee of Chinese Anti-Cancer Association.

Dr. Yu is the inventor of more than 60 patents and has published more than 50 SCI scientific papers and monographs. Dr. Yu has been awarded as "China's Top Ten Innovative Figures" in 2014, "Ernst & Young Entrepreneur Award" in 2015, "Excellent Entrepreneur in Jiangsu Province" in 2016, "Top Ten National Science and Technology Innovation Figures in 2016", "2017 China Person of the Year in Pharmaceutical Economics, 2017 Most Influential Person in Life Sciences in China, First Prize of the 7th Overseas Chinese Community Contribution Award in 2018, etc.